Ionis Pharmaceuticals, Inc.
(NASDAQ : ISIS)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
CELGCelgene Corporation
0.79%89.351.3%$810.33m
AMGNAmgen Inc.
1.45%188.201.2%$638.15m
GILDGilead Sciences, Inc.
0.52%65.890.9%$484.79m
BIIBBiogen Inc.
0.89%324.041.3%$431.26m
ILMNIllumina, Inc.
1.39%301.023.5%$315.69m
REGNRegeneron Pharmaceuticals, Inc.
0.59%421.072.6%$291.88m
VRTXVertex Pharmaceuticals Incorporated
0.97%184.841.9%$256.05m
ALXNAlexion Pharmaceuticals, Inc.
1.01%128.842.0%$221.90m
SRPTSarepta Therapeutics, Inc.
1.82%139.0215.4%$155.10m
AAgilent Technologies, Inc.
0.09%77.961.6%$150.94m
EXASExact Sciences Corporation
8.71%90.5425.3%$143.81m
INCYIncyte Corporation
1.19%84.322.5%$113.26m
ARRYArray BioPharma Inc.
3.39%23.488.2%$111.67m
EXELExelixis, Inc.
0.75%21.386.4%$82.68m
NBIXNeurocrine Biosciences, Inc.
1.79%78.695.1%$78.60m

Company Profile

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core and Akcea Therapeutics segments. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs. The Akcea Therapeutics segment develops and commercializes drugs for cardiometabolic diseases. The company was founded by Stanley T. Crooke and Brett P. Monia on January 10, 1989 and is headquartered in Carlsbad, CA.